In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a bold move, the U.S. Department of Health and Human Services is restructuring to save $1.8 billion annually while tackling America's chronic illness epidemic. With a workforce reduction and consolidation of divisions, the new plan promises efficiency and better health outcomes.